The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...
From loss of skin elasticity to hair density, supplements that offer targeted support for GLP-1 users, as well as those that ...
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review series. This multipart special ...
A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...
Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...
The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.
The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...
Most people have missed a dose of prescription medication at some point. But if you are taking a glucagon-like peptide-1 drug ...
Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...
On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...